Dose-related neuropathic and anti-neuropathic effects of simvastatin in vincristine-induced neuropathic pain in rats.
The present study explores the role of simvastatin in vincristine-induced neuropathic pain, which was induced by administering vincristine (100 µg/kg i.p.) for 10 days (two 5 day cycles with 2 days pause). Pain was assessed by determining mechanical hyperalgesia, mechanical dynamic allodynia, heat hyperalgesia and cold allodynia. Biochemically, myeloperoxidase (MPO) activity was measured along with serum cholesterol levels. Simvastatin (7.5, 15 and 30 mg/kg) was administered for 14 days after administration of vincristine. Simvastatin (7.5 and 15 mg/kg) reversed vincristine-induced neuropathic pain and attenuated vincristine-induced increase in MPO, without altering cholesterol levels. Simvastatin at higher dose (30 mg/kg) did not alter neuropathic pain despite decreasing MPO levels. Furthermore, administration of simvastatin (30 mg/kg i.p.) in vincristine treated rats as well as it's per se administration in normal rats reduced cholesterol levels. Per se administration of simvastatin in normal rats produced neuropathic pain. It is concluded that simvastatin attenuates neuropathic pain only at lower doses with no reduction in cholesterol levels and anti-inflammatory effects may possibly reverse neuropathic pain. However, despite reducing inflammation, simvastatin did not confer beneficial effects at higher doses at which there is reduction in cholesterol levels, suggesting the critical role of cholesterol in neuropathic pain induction.
Department of Pharmaceutical Sciences and Drug Research, Punjabi University Patiala, 147002, India.
Shrutya
S
Bhalla
Department of Pharmaceutical Sciences and Drug Research, Punjabi University Patiala, 147002, India.
Nirmal
N
Singh
Department of Pharmaceutical Sciences and Drug Research, Punjabi University Patiala, 147002, India. Electronic address: amteshwarjaggi@yahoo.co.in.
Amteshwar Singh
AS
Jaggi
D000818:Animals; D002784:Cholesterol / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005260:Female; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D009437:Neuralgia / Q000139:chemically induced* / Q000188:drug therapy; D009195:Peroxidase / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D019821:Simvastatin / Q000008:administration & dosage / Q000494:pharmacology*; D050257:Tubulin Modulators / Q000633:toxicity*; D014750:Vincristine / Q000633:toxicity*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D050257:Tubulin Modulators; D014750:Vincristine; D002784:Cholesterol; D019821:Simvastatin; D009195:Peroxidase
Cholesterol; Inflammation; Neuropathic pain; Vincristine